 |
|
|
|
|
|
|
|
|
|
|
 |
|
|||||||||
 |
 |
 |
 |
 |
 |
 |
 |
|
||
 |
 |
 |
|
|||||||
 |
|
|||||||||
 |
|
|||||||||
Alert Number 248
Date: September 1, 2024
CLL and lymphoma patients are facing the prospect that a valuable, FDA approved therapy option may become unavailable because of proposed changes in Medicare/Medicaid reimbursement schedules. You can read about the therapy and issues involved in our announcement on the subject: Radioimmunotherapy Reimbursement Cuts. A patient initiative has been launched to appeal against these changes. Please take a minute to read about this issue and take action by adding your endorsement to the patient initiative.
For some background on how radioimmunotherapy is relevant to CLL, you might want to read our recent article, Bexxar: An introduction to Radioimmunotherapy.
Be proactive. Be well,
P. C. Venkat
_______
NOTICE: This page from the Topics Alert archive was originally emailed to subscribers of Topics Alert, a free service of CLL Topics Inc. If you are not a subscriber and you wish to receive email Alerts, please register at the Topics Alert subscription page. The content of this page is intended for information only and it is NOT meant to be medical advice. Please be sure to consult and follow the advice of your doctors on all medical matters.
———
Disclaimer: The content of this website is intended for information only and is NOT meant to be medical advice. Please be sure to consult and follow the advice of your doctors on all medical matters.
Copyright Notice:
Copyright © 2024-2007 CLL Topics, Inc. All Rights Reserved.
All materials contained on this site are protected by United States copyright law and may not be reproduced, distributed, transmitted, displayed, published or broadcast without the prior written permission of CLL Topics, Inc. You may not alter or remove any trademark, copyright or other notice from copies of the content.
However, you may download and print material from CLLTopics.org exclusively for your personal, noncommercial use.
———
